UBS Initiates Coverage On MBX Biosciences with Buy Rating, Announces Price Target of $60
Benzinga Newsdesk 9 months ago
NewsPrice TargetInitiationAnalyst Ratings
UBS analyst Michael Yee initiates coverage on MBX Biosciences (NASDAQ:MBX) with a Buy rating and announces Price Target of $60.
UBS analyst Michael Yee initiates coverage on MBX Biosciences (NASDAQ:MBX) with a Buy rating and announces Price Target of $60.